Full Papers
Comparison of serum exosome miRNA from patients with Raynaud’s phenomenon with positive and negative serum antinuclear antibodies
S. Piera-Velazquez1, P. Fortina2, S.A. Jimenez3
- Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, USA.
- Cancer Genomics and Bioinformatics Laboratory, Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
- Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, USA. sergio.jimenez@jefferson.edu
CER17708
2024 Vol.42, N°8
PI 1629, PF 1634
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 39152754 [PubMed]
Received: 22/03/2024
Accepted : 03/06/2024
In Press: 01/08/2024
Published: 14/08/2024
Abstract
OBJECTIVES:
To compare the microRNAs (miRNAs) contained within serum exosomes isolated from patients with Raynaud’s phenomenon (RP) and negative antinuclear antibodies (ANA) to the miRNA contained in serum exosomes isolated from patients with RP and positive ANA.
METHODS:
Serum exosomes were isolated employing a polymer precipitation procedure. Next Generation Sequencing (NGS) was used to identify the miRNAs contained in the exosomes isolated from the two clinical cohorts and to analyse the differences in their contents.
RESULTS:
The NGS results identified six miRNAs that displayed significant differences in their content between serum exosomes from patients with RP with negative serum ANA compared to miRNAs contained in serum exosomes from patients with ANA-positive RP.
CONCLUSIONS:
A comparative analysis of miRNAs contained within serum exosomes of patients with RP and negative ANA vs. samples from patients with RP and positive ANA identified several differentially expressed miRNAs that may represent non-invasive biomarkers to assist in the identification of patients with RP at risk of evolving into systemic sclerosis.
